These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30645831)

  • 1. Canagliflozin: increased risk of toe amputations? Do not use this drug in diabetes.
    Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30645831
    [No Abstract]   [Full Text] [Related]  

  • 2. In brief: Canagliflozin and lower limb amputations.
    Med Lett Drugs Ther; 2020 Sep; 62(1607):152. PubMed ID: 32960870
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 5. SGLT2 inhibitors and lower limb complications: an updated meta-analysis.
    Lin C; Zhu X; Cai X; Yang W; Lv F; Nie L; Ji L
    Cardiovasc Diabetol; 2021 Apr; 20(1):91. PubMed ID: 33910574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
    Khouri C; Cracowski JL; Roustit M
    Diabetes Obes Metab; 2018 Jun; 20(6):1531-1534. PubMed ID: 29430814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.
    Fralick M; Kim SC; Schneeweiss S; Everett BM; Glynn RJ; Patorno E
    BMJ; 2020 Aug; 370():m2812. PubMed ID: 32843476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
    Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
    Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
    Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
    Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
    Diabetes Obes Metab; 2018 Dec; 20(12):2792-2799. PubMed ID: 29971914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
    Misher A; Ampuero A; Phan R; Aziz S; Ebong E; Braich J; Dyches K; Southwood R
    Am J Ther; 2020 Mar; 28(1):e96-e110. PubMed ID: 32384319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.
    Fadini GP; Avogaro A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):680-681. PubMed ID: 28733172
    [No Abstract]   [Full Text] [Related]  

  • 14. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.
    Koch RA; Clark RF
    Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848
    [No Abstract]   [Full Text] [Related]  

  • 15. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
    Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
    Masuta P; Johri G; Paul M
    Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
    Khan MS; Usman MS; Siddiqi TJ; Memon MM; Shah SJ; Khan SS
    Eur J Prev Cardiol; 2019 Oct; 26(15):1680-1682. PubMed ID: 30755019
    [No Abstract]   [Full Text] [Related]  

  • 18. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Induced Necrotizing Pancreatitis With a Focus on Canagliflozin.
    Patel KM; Pikas E; George T
    Am J Ther; 2017; 24(4):e496. PubMed ID: 28639964
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
    Tanaka A; Node K
    Cardiovasc Diabetol; 2017 Oct; 16(1):129. PubMed ID: 29025400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.